Institutional Investors Show Diverging Views on Johnson & Johnson Stock
02.01.2026 - 11:22:04
Johnson & Johnson shares are trading near record highs, yet major institutional investors are sending mixed signals through their recent portfolio adjustments. Fresh regulatory filings reveal significant buying and selling activity among large funds, highlighting a split in sentiment regarding the healthcare giant’s valuation. This comes as the company finalizes a major strategic acquisition.
A key development influencing Johnson & Johnson’s current valuation is its completed purchase of Halda Therapeutics. The $3.05 billion all-cash deal, closed on December 29, 2025, brings the biotechnology firm’s targeted cancer therapy platform into J&J’s portfolio.
While the acquisition is expected to bolster the company’s long-term Read more...
@ boerse-global.de | US4781601046 INSTITUTIONAL
